PKN1 Fusion Detection via Segmented FISH and PCR Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective identification and treatment strategies for cancers characterized by PKN1 gene fusions, which result in aberrant expression or overexpression of the PKN1 kinase, leading to conditions like lung and liver cancers.
Innovation Solution
Developing methods to detect PKN1 fusions in biological samples using specific reagents and nucleic acid sequences, and employing PKN1 inhibitors to treat associated cancers by targeting the aberrant kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current general cancer detection methods are used, then broad cancer screening is possible, but specific identification of PKN1 fusion-positive cancers is not achieved
Solution Approach 1:
The patent divides the detection process into multiple specialized components: FISH probes targeting specific PKN1 fusion breakpoints, PCR primers for fusion-specific amplification, and immunohistochemical markers. This segmentation allows precise identification of PKN1 fusion-positive cancers while maintaining manageable complexity through modular test design.
Solution Approach 2:
The patent introduces intermediary molecules including fusion-specific FISH probes that hybridize to PKN1 fusion transcripts, PCR primers that amplify fusion-specific sequences, and antibodies that detect PKN1 fusion proteins. These intermediaries enable specific detection without requiring direct observation of the fusion event itself.
2Adaptability or versatility
If PKN1 fusion detection is implemented, then personalized treatment selection is improved, but diagnostic time and resource requirements increase
Solution Approach 1:
The patent employs preliminary action by using FISH probes and PCR primers that are pre-designed to target specific PKN1 fusion breakpoints and sequences. This allows rapid detection without requiring de novo sequence analysis, significantly reducing diagnostic time while maintaining personalized medicine capabilities.
Solution Approach 2:
The patent utilizes parameter changes by detecting PKN1 fusions through multiple modalities (fluorescence signals from FISH, amplification products from PCR, protein expression from IHC) that can be optimized for different clinical scenarios, balancing speed and precision based on specific diagnostic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate diagnosis and personalized treatment of cancers with PKN1 fusions, potentially improving patient outcomes by inhibiting aberrant PKN1 activity and reducing tumor growth.
Implementation Method 1
contacting the sample with a reagent that detects a PKN1 fusion
Data Source
AI summary
The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.